ABO incompatible renal transplant: Transfusion medicine perspective.

Asian J Transfus Sci

Department of Transfusion Medicine and Immunohematology, Indraprastha Apollo Hospitals, New Delhi, India.

Published: January 2017

Introduction: Our study presents an analysis of the trends of ABO antibody titers and the TPE (Therapeutic Plasma Exchange) procedures required pre and post ABO incompatible renal transplant.

Materials And Methods: Twenty nine patients underwent ABO incompatible renal transplant during the study period. The ABO antibody titers were done using the tube technique and titer reported was the dilution at which 1+ reaction was observed. The baseline titers of anti-A and anti-B antibodies were determined. The titer targeted was ≤8. Patients were subjected to 1 plasma volume exchange with 5% albumin and 2 units of AB group FFP (Fresh Frozen Plasma) in each sitting. TPE procedures post-transplant were decided on the basis of rising antibody titer with/ without graft dysfunction.

Results: The average number of TPE procedures required was 4-5 procedures/patient in the pretransplant and 2-3/patient in the post-transplant period. An average titer reduction of 1 serial dilution/procedure was noted for Anti-A and 1.1/procedure for Anti-B. Number of procedures required to reach the target titer was not significantly different for Anti-A and Anti-B ( = 0.98). Outcome of the transplant did not differ significantly by reducing titers to a level less than 8 ( = 0.32). The difference in the Anti-A and Anti-B titers at 14th day post-transplant was found to be clinically significant ( = 0.042).

Conclusion: With an average of 4-5 TPE procedures pretransplant and 2-3 TPE procedures post transplants, ABO incompatible renal transplantations can be successfully accomplished.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5345280PMC
http://dx.doi.org/10.4103/0973-6247.200767DOI Listing

Publication Analysis

Top Keywords

abo incompatible
16
incompatible renal
16
tpe procedures
16
procedures required
12
anti-a anti-b
12
renal transplant
8
abo antibody
8
antibody titers
8
abo
6
procedures
6

Similar Publications

Objectives: Neonatal hyperbilirubinemia, or newborn jaundice, is a common condition caused by high bilirubin levels. Blood group incompatibility between mother and baby is a major cause. This study examined the link between different blood group incompatibilities and their management in newborns with jaundice.

View Article and Find Full Text PDF
Article Synopsis
  • This study investigates the balance between avoiding platelet wastage and ensuring transfusion efficacy, focusing on the effects of platelet compatibility and product modification on reaction rates.
  • A review of over 21,000 platelet transfusions revealed a 1.33% reaction rate, with major incompatibility and irradiated products associated with increased odds of adverse reactions.
  • The findings suggest that both platelet compatibility and product modification independently impact transfusion reactions, informing future policies for selecting platelet products for patients.
View Article and Find Full Text PDF

Background: This study aimed to investigate the association between the Fc-gamma receptor IIIA (FCGR3A) 158 polymorphism and clinical outcomes in kidney transplantation (KTx) patients. Specifically, we focused on late-onset neutropenia (LON) in ABO-incompatible (ABOi) or HLA-incompatible (HLAi) KTx recipients who underwent rituximab (RTx) desensitization therapy.

Methods: FCGR3A 158F/V polymorphisms were identified in 85 ABOi or HLAi KTx recipients who underwent RTx desensitization at our institution between April 2008 and October 2021.

View Article and Find Full Text PDF

BACKGROUND Despite its surgical complexity, kidney transplantation (KT) with multiple renal arteries (MRA) is comparable in performance to KT with a single renal artery (SRA). This study aimed to evaluate the effect of MRA and to investigate risk factors for graft loss in living-donor KT with MRA. MATERIAL AND METHODS This study included living-donor KT recipients who underwent KT in our hospital from February 2002 to March 2023.

View Article and Find Full Text PDF

Major ABO Incompatibility in Non-Myeloablative Hematopoietic Stem Cell Transplant for Sickle Cell Disease-Not an Insurmountable Obstacle.

Pediatr Blood Cancer

January 2025

Blood and Marrow Transplant/Cellular Therapy Program, Division of Hematology/Oncology, The Hospital for Sick Children, Toronto, Ontario, Canada.

With advances in conditioning strategies and graft-versus-host disease (GvHD) prevention, hematopoietic stem cell transplantation (HSCT) is a safe, curative treatment option for pediatric patients with sickle cell disease (SCD). However, donor options have been limited in non-myeloablative matched sibling donor (MSD) setting by excluding recipients with major ABO blood group incompatible donors due to concern of the risk of significant complications such as pure red cell aplasia (PRCA). We present three cases of successful HSCT with major ABO incompatibility with their donors, and discuss strategies to safely expand the donor pool to include these donors.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!